Akebia Therapeutics announced that it has regained full rights to the oral drug Vafseo (vadadustat) for chronic kidney disease anemia after its commercialization partner CSL Vifor agreed to terminate their contract.
Tag Archive for: CSL Vifor
Among the recent layoffs: The Labor Day long weekend began on a sour note for more than half of the employees at Maryland–based NexImmune. The biotech, which is developing immunotherapies for cancer, autoimmune and infectious diseases, announced it will lay off approximately 53% of its staff, turning a workforce of 47 full-time employees into one of just 22 as of September 5.